Durvalumab monotherapy did not meet the prespecified statistical threshold for DFS versus active monitoring, despite a 6-point absolute 3-year DFS difference (78% vs 72%). RAMPART enrolled ...

Approval is based on data from the ASCERTAIN-V clinical trial demonstrating that INQOVI in combination with venetoclax met complete response endpoints, with no new safety concerns reported INQOVI is ...

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has approved INQOVI (decitabine and cedazuridine) plus venetoclax as a ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. The combination of decitabine-cedazuridine ...

In the ASCERTAIN-V trial, treatment with decitabine/cedazuridine plus venetoclax yielded a complete remission (CR) rate of 41.6% and a CR/CRh rate of 52.5% in patients ineligible for intensive ...

Histoplasmosis is an endemic mycosis that primarily affects the lungs, commonly found in the central and eastern United States, particularly the Ohio and Mississippi River valleys. While disseminated ...

Germline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors ERRFI1 mutations represent actionable biomarkers in BTC, with EGFR-targeted therapy demonstrating ...

Beyond-line immunotherapy in ES-SCLC: Efficacy and safety of second-line PD-1/PD-L1 inhibitors after progression on first-line PD-1/PD-L1 inhibitors plus platinum-etoposide chemotherapy. This is an ...